| Literature DB >> 35615742 |
Justin Lau1, Claude Regis1, Christina Burke2, MaryJo Kaleda2, Raymond McKenna2, Lisa M Muratori2.
Abstract
Background: Parkinson's disease (PD) is a neurodegenerative disease in which the progressive loss of dopaminergic neurons (DA) leads to initially sporadic and eventually widespread damage of the nervous system resulting in significant musculoskeletal and cognitive deterioration. Loss of motor function alongside increasing cognitive impairment is part of the natural disease progression. Gait is often considered an automatic activity; however, walking is the result of a delicate balance of multiple systems which maintain the body's center of mass over an ever-changing base of support. It is a complex motor behavior that requires components of attention and memory to prevent falls and injury. In addition, evidence points to the critical role of salient visual information to gait adaptability. There is a growing understanding that treatment for PD needs to address movement as it occurs naturally and walking needs to be practiced in more complex environments than traditional therapy has provided.Entities:
Keywords: cognitive-motor interference; dual task; gait; gaming; neurodegenerative disease; physical therapy; rehabilitation
Year: 2022 PMID: 35615742 PMCID: PMC9124833 DOI: 10.3389/fnhum.2022.863930
Source DB: PubMed Journal: Front Hum Neurosci ISSN: 1662-5161 Impact factor: 3.473
Participant demographics.
| Participant ID | Sex | Age | H&Y stage | PD medications | Baseline gait velocity | Baseline MoCA |
| E1 | F | 68 | 1 | Y | 0.93 | 27 |
| E2 | M | 75 | 2 | Y | 0.96 | 26 |
| E3 | M | 57 | 2 | Y | 1.02 | 27 |
| E4 | F | 57 | 2 | Y | 0.99 | 29 |
| E5 | M | 71 | 3 | Y | 0.95 | 23 |
| E6 | M | 59 | 2 | N | 0.94 | 28 |
| E7 | M | 64 | 1.5 | Y | 1.09 | 23 |
| E8 | M | 48 | 2 | Y | 1.04 | 25 |
| E9 | F | 70 | 2.5 | Y | 0.69 | 26 |
| Mean (SD) |
|
|
|
|
|
|
| C1 | M | 78 | 2 | Y | 0.72 | 23 |
| C2 | F | 69 | 2 | Y | 1.05 | 25 |
| C3 | M | 73 | 3 | Y | 0.92 | 26 |
| C4 | M | 79 | 2.5 | Y | 0.83 | 18 |
| C5 | M | 65 | 1 | Y | 1.17 | 29 |
| C6 | F | 72 | 2 | Y | 0.87 | 24 |
| C7 | F | 72 | 1.5 | Y | 1.17 | 28 |
| C8 | M | 66 | 2 | Y | 1.01 | 30 |
| C9 | M | 67 | 1 | Y | 1.08 | 30 |
| Mean (SD) |
|
|
|
|
|
|
Sex, Age, Hoehn and Yahr (H&Y) stage, use of PD medication, baseline velocity, and baseline MoCA score for individual participants in each group. Participants in the Experimental group (E1–E9) and Control group (C1–C9) were equivalent at baseline (p > 0.05 for all comparisons). There was only one participant (E6) that was not taking medication (dopamine, dopamine agonists, anticholinergics, COMT or MAO inhibitors) for PD. Means and SD are in bold.
FIGURE 1Experimental set-up. (A) Experimental set-up including a split-belt treadmill, overhead safety harness (no bodyweight support), large button controllers (to turn in the game left or right and reverse directions and to select the correct change following a delivery), projector and screen. A separate computer work station to the right of the participant allowed the research clinician to control treadmill speed and inclination. Both the treadmill and the computer workstation had emergency stop capability. (B) Level one of the immersive game: Participants are shown a map with the location of the participant in the game (red dot), target location for delivery (yellow dot), and location of three thieves moving around the game (green dots). (C) Level two of the immersive game: Participants are shown the map of the town but are no longer provided with dots to show where they are, where they need to go, or where the thieves are located. The dialogue in the center of the screen is a typical starting instructional prompt. Level three has the same type of prompt but the map is no longer visible. (D) Level four of the immersive game: similar to level three, the map is not visible in level four. The dialogue in the center shows that the instructional prompt now has a more complex price and the calculation required at delivery is similarly more difficult.
FIGURE 2Motor outcomes comparing baseline to 1 month post. Individual change scores from baseline to 1-month for participants in the experimental (E1–E9) and control (C1–C9) groups. The solid line at 0 represents no change at the 1-month post assessment (zero change). The dashed lines show the level reported for clinically meaningful change in the respective variable. (A) Change in gait velocity. An increase of 0.14 m/s (top dashed line) or more represents a clinically meaningful change in velocity for individuals with PD. Six of the nine participants in the experimental group improved at or past the dashed line while only two of the nine control participants demonstrated that amount of improvement. (B) Change in distance for the 6 MWT. The dashed line represents a change of 30 m as an increase (top dashed line) of that amount has been shown to represent a clinically meaningful change in the 6 MWT for individuals with PD. Seven of the nine participants in the experimental group improved at or past the dashed line while only two of the nine control participants demonstrated that amount of improvement. (C) Change scores for TUG. A decrease of 0.3 m/s (bottom dashed line) has been shown to represent a clinically meaningful change on this outcome measure. Three of the nine participants in the experimental group improved at or past the dashed line while none of the control participants demonstrated meaningful improvement. (D) Change scores for TUG Cognitive The dashed line represents a change of 3 s in either direction and was chosen to match the criteria for the TUG. Three of the nine participants in the experimental group improved while none of the control participants demonstrated that amount of improvement.
FIGURE 3Cognitive outcomes comparing baseline to 1 month post. Individual change scores from baseline to 1-month for participants in the experimental (E1–E9) and control (C1–C9) groups. The solid line at 0 represents no change at the 1-month post assessment (zero change). The dashed lines show the level reported for clinically meaningful change in the respective variable. (A) Change scores for MoCA. The dashed line represents a change of 3-points in either direction. An increase (top dashed line) of that amount has been shown to represent a clinically meaningful change on this outcome measure. While the experimental group showed a consistent, significant improvement (p = 0.007) with all nine participants improving on the follow-up test, only two improved by 3 or more points. The control participants did not demonstrate a significant change and showed a more varied pattern, with four participants improving and the other five remaining the same or worse at 1-month testing. (B) Change scores for SDMT. The dashed line represents a change of 8-points in either direction. An increase (top dashed line) of that amount has been shown to represent a clinically meaningful change on the SDMT. While the experimental group showed a consistent, significant improvement (p = 0.01) with eight of nine participants improving on the follow-up test, both the experimental and control groups had only two participants improve 8 or more points. The control participants did not demonstrate a significant change and four of the control participants had a poorer performance at 1-month testing.